Want to see MBRX full AI Analyst Report?

Moleculin Biotech (MBRX) Price & Analysis

Q: What was Moleculin Biotech’s price range in the past 12 months?

Moleculin Biotech lowest stock price was $3.22 and its highest was $315.42 in the past 12 months.

Q: What is Moleculin Biotech’s market cap?

Moleculin Biotech’s market cap is $110.77M.

Q: When is Moleculin Biotech’s upcoming earnings report date?

Moleculin Biotech’s upcoming earnings report date is Mar 19, 2027 which is in 149 days.

Q: How were Moleculin Biotech’s earnings last quarter?

Moleculin Biotech released its earnings results on Aug 14, 2026. The company reported -$28 earnings per share for the quarter, beating the consensus estimate of -$31.067 by $3.067.

Q: Is Moleculin Biotech overvalued?

According to Wall Street analysts Moleculin Biotech’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Q: Does Moleculin Biotech pay dividends?

Moleculin Biotech does not currently pay dividends.

Q: What is Moleculin Biotech’s EPS estimate?

Moleculin Biotech’s EPS estimate for its next earnings report is not yet available.

Q: How many shares outstanding does Moleculin Biotech have?

Moleculin Biotech has 20,900,000 shares outstanding.

Q: What happened to Moleculin Biotech’s price movement after its last earnings report?

Moleculin Biotech reported an EPS of -$28 in its last earnings report, beating expectations of -$31.067. Following the earnings report the stock price went up 7.159%.

Q: Which hedge fund is a major shareholder of Moleculin Biotech?

Currently, no hedge funds are holding shares in MBRX

2,021 Followers

MBRX Stock Chart & Stats

$0.61

$0.04(1.92%)

At close: Jul 24 4:00 PM EDT

$0.61

$0.04(1.92%)

Day’s Range― - ―

52-Week Range$3.22 - $315.42

Previous CloseN/A

Volume44.49K

Average Volume (3M)964.48K

Market Cap

$110.77M

Enterprise Value$8.88M

Total Cash (Recent Filing)$7.26M

Total Debt (Recent Filing)$292.00K

Price to Earnings (P/E)―

Beta1.19

Next Earnings

Mar 19, 2027

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-342.60

Shares Outstanding20,900,000

10 Day Avg. Volume436,427

30 Day Avg. Volume964,484

Financial Highlights & Ratios

PEG Ratio<0.01

Price to Book (P/B)0.26

Price to Sales (P/S)0.00

P/FCF Ratio-0.17

Enterprise Value/Market Cap0.08

Enterprise Value/RevenueN/A

Enterprise Value/Gross Profit-1.11K

Enterprise Value/Ebitda-0.29

Forecast

1Y Price Target

$240.00

Price Target Upside39244.26% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering3

EPS Forecast (FY)-73.8

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Clinical Program ProgressCompleting enrollment in a pivotal Phase 2/3 AML trial with a broad fit and unfit cohort creates a defined clinical catalyst and improves the evidence base for dose selection and regulatory progression. It also shows the lead program has advanced beyond early feasibility.

Cardiac Safety DifferentiationIndependent peer-reviewed findings showing no observed cardiotoxicity across 90 patients support Annamycin’s potential differentiation from traditional anthracyclines. If maintained in later development, this safety profile could expand treatment utility and strengthen the drug’s positioning in difficult oncology indications.

Long-Dated Intellectual PropertyPatent protection through 2040 provides a durable exclusivity foundation for the lung-targeted liposomal Annamycin platform. Broadening protection beyond the lead AML program may support future development in pulmonary tumors and improve the company’s strategic position if clinical validation continues.

Bears Say

Pre-Revenue Operating ModelWith no reported revenue and persistent losses of roughly $30.3 million on a trailing basis, Moleculin has not yet demonstrated commercial revenue generation or operating leverage. The business therefore remains dependent on successful clinical development before it can establish a self-sustaining earnings base.

Persistent Cash BurnOperating and free cash flow of approximately negative $25.4 million show that current activities consume substantial cash rather than fund themselves. Continued burn increases the company’s need for external capital and may constrain its ability to finance clinical programs without affecting shareholder ownership.

Nasdaq Listing And Capital Access RiskFailure to meet Nasdaq’s minimum bid requirement creates a structural risk to continued exchange listing and investor access. Although a hearing process is available, an adverse outcome could reduce financing flexibility, weaken market access, and complicate support for ongoing clinical development.

Moleculin Biotech News

Moleculin Biotech trading halted, news pending

19:50 EDT Moleculin Biotech (MBRX) trading halted, news pending Published first on TheFly – the ultimate source for...

2d ago

MBRX

Upcoming Stock Splits This Week (October 19 to October 23) – Stay Invested

Let’s take a look at the upcoming stock splits for the week of October 19 to October 23,...

3d ago

Moleculin Biotech announces 1-for-20 reverse stock split

Moleculin Biotech (MBRX) announced that it filed an amendment to its amended and restated certificate of incorporation with...

5d ago

MBRX

Moleculin Biotech completes enrollment in Part A of Phase 2/3 R/R MIRACLE trial

Moleculin Biotech (MBRX) announced that it has completed and closed enrollment in Part A of its Phase 2/3...

22d ago

MBRX

Moleculin Biotech announces publication of analysis of Annamycin in Frontiers

Moleculin Biotech (MBRX) announced the publication of a peer-reviewed analysis of the cardiac safety of Annamycin in Frontiers...

23d ago

MBRX

Moleculin Biotech secures Mexican patent protecting Annamycin through 2040

Moleculin Biotech (MBRX) announced that the Mexican Patent Office has granted Patent No. 436849, further strengthening the Company’s...

28d ago

MBRX

Moleculin Biotech Executes 1-for-20 Reverse Stock Split

Moleculin Biotech ( ($MBRX) ) has shared an announcement. On October 9, 2026, Moleculin Biotech stockholders approved an...

1d ago

MBRX

Moleculin Biotech Updates Investors With New Presentation

Moleculin Biotech ( ($MBRX) ) has issued an update. On October 16, 2026, Moleculin Biotech, Inc. released a...

5d ago

MBRX

Moleculin Biotech Shareholders Approve Key Annual Meeting Actions

Moleculin Biotech ( ($MBRX) ) has shared an announcement. On October 9, 2026, Moleculin Biotech held its Annual...

12d ago

MBRX

Moleculin Biotech Updates Investors With New Presentation

Moleculin Biotech ( ($MBRX) ) has provided an announcement. On October 5, 2026, Moleculin Biotech, Inc. used a...

16d ago

MBRX

Sara Nik Reiterates Buy on Moleculin as MIRACLE Trial De‑Risks AnnAraC; $3 Price Target Maintained

H.C. Wainwright analyst Sara Nik maintained a Buy rating on Moleculin Biotech today and set a price target...

22d ago

MBRX

Moleculin Completes Enrollment in Pivotal AML Trial

Moleculin Biotech ( ($MBRX) ) has issued an announcement. On September 29, 2026, Moleculin Biotech reported it has...

22d ago

MBRX

Moleculin Highlights Annamycin Cardiac Safety in New Analysis

An update from Moleculin Biotech ( ($MBRX) ) is now available. On September 28, 2026, Moleculin Biotech announced...

23d ago

MBRX

Moleculin Highlights Immune-Driven Annamycin Pancreatic Cancer Data

Moleculin Biotech ( ($MBRX) ) has provided an update. On September 25, 2026, Moleculin Biotech reported new preclinical...

26d ago

MBRX

MBRX FAQ

What was Moleculin Biotech’s price range in the past 12 months?

Moleculin Biotech lowest stock price was $3.22 and its highest was $315.42 in the past 12 months.

What is Moleculin Biotech’s market cap?

Moleculin Biotech’s market cap is $110.77M.

When is Moleculin Biotech’s upcoming earnings report date?

Moleculin Biotech’s upcoming earnings report date is Mar 19, 2027 which is in 149 days.

How were Moleculin Biotech’s earnings last quarter?

Moleculin Biotech released its earnings results on Aug 14, 2026. The company reported -$28 earnings per share for the quarter, beating the consensus estimate of -$31.067 by $3.067.

Is Moleculin Biotech overvalued?

According to Wall Street analysts Moleculin Biotech’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Moleculin Biotech pay dividends?

Moleculin Biotech does not currently pay dividends.

What is Moleculin Biotech’s EPS estimate?

Moleculin Biotech’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Moleculin Biotech have?

Moleculin Biotech has 20,900,000 shares outstanding.

What happened to Moleculin Biotech’s price movement after its last earnings report?

Moleculin Biotech reported an EPS of -$28 in its last earnings report, beating expectations of -$31.067. Following the earnings report the stock price went up 7.159%.

Which hedge fund is a major shareholder of Moleculin Biotech?

Currently, no hedge funds are holding shares in MBRX

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Moleculin Biotech Stock Smart Score

Underperform

Fundamentals

Return on Equity

-816.56%

Trailing 12-Months

Asset Growth

-2.34%

Trailing 12-Months

Learn more about TipRanks Smart Score

Top Smart Score Stocks >

Company Description

Moleculin Biotech

Moleculin Biotech, Inc. is a clinical-stage pharmaceutical company dedicated to advancing therapeutic candidates designed to combat highly aggressive cancers and viral infections. Their primary investigational drug, Annamycin, is currently undergoing Phase 1/2 clinical trials. These trials aim to assess its efficacy against acute myeloid leukemia (AML) that has relapsed or is resistant to prior therapies, as well as malignancies that have spread to the lungs. WP1066, a prominent immune/transcription modulator for the company, is presently in Phase I studies, targeting both adult and pediatric brain tumors, pancreatic cancer, and other types of aggressive malignancies. Further, the firm is developing WP1220, an analog of WP1066, intended for topical application in treating cutaneous T-cell lymphoma. Another compound, WP1122, is under development for glioblastoma multiforme and COVID-19. Moleculin Biotech has established collaboration agreements and partnerships with organizations such as MD Anderson, Animal Life Sciences, LLC, and WPD Pharmaceuticals Sp z.o.o. The company was founded in 2015 and maintains its principal offices in Houston, Texas.

Moleculin Biotech (MBRX) Earnings & Revenues

Historic Earnings Reports

MBRX Stock 12 Month Forecast

Average Price Target

$240.00

▲(39244.26% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"7":"$7","314":"$314","621":"$621","160.5":"$160.5","467.5":"$467.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":620,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$620.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":240,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$240.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":40,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$40.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[7,160.5,314,467.5,621],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jan<br/>2026","6":"Apr<br/>2026","9":"Jul<br/>2026","12":"Oct<br/>2026","25":"Oct<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,10.075,56.99230769230769,103.90961538461538,150.82692307692304,197.74423076923074,244.66153846153844,291.5788461538461,338.4961538461538,385.4134615384615,432.3307692307692,479.2480769230769,526.1653846153846,573.0826923076922,{"y":620,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,10.075,27.76153846153846,45.448076923076925,63.13461538461539,80.82115384615385,98.50769230769231,116.19423076923077,133.88076923076923,151.56730769230768,169.25384615384615,186.9403846153846,204.62692307692305,222.31346153846152,{"y":240,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,10.075,12.376923076923077,14.678846153846154,16.98076923076923,19.282692307692308,21.584615384615386,23.886538461538464,26.18846153846154,28.490384615384617,30.792307692307695,33.094230769230776,35.39615384615385,37.698076923076925,{"y":40,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":264.999,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":232.7,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":132.6,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":66.2,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":82.399,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":47.6,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":44.6,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":50.2,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":52.8,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":53.8,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8,"date":1785542400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13,"date":1788220800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.075,"date":1790812800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >